Trial Profile
Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms SOTHIS
- Sponsors AbbVie
- 15 Feb 2022 Planned End Date changed from 7 Feb 2024 to 29 Apr 2029.
- 15 Feb 2022 Planned primary completion date changed from 7 Feb 2024 to 29 Apr 2029.
- 18 Mar 2021 Planned End Date changed from 20 Nov 2028 to 7 Feb 2024.